No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

No­var­tis is pluck­ing a Phase I small mol­e­cule can­di­date out of Ko­rea that it be­lieves can treat a va­ri­ety of dis­eases — in­clud­ing cer­tain car­dio­vas­cu­lar con­di­tions.

Hand­ing Chong Kun Dang Phar­ma­ceu­ti­cal (CKD) an up­front pay­ment of $80 mil­lion, No­var­tis bought ex­clu­sive rights to an HDAC6 in­hibitor, dubbed CKD-510, every­where in the world ex­cept in Ko­rea. Mile­stones can add up to $1.225 bil­lion be­fore count­ing tiered roy­al­ties, mak­ing it CKD’s largest con­tract ever, CEO Kim Young-Joo told Ko­rea Bio­Med.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER